

Philip J Beale

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8918031/philip-j-beale-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

5,500
citations

35
h-index

73
g-index

120
ext. papers

6,298
ext. citations

4.7
avg, IF

4.93
L-index

#	Paper	IF	Citations
116	Staff perspectives on the feasibility of a clinical pathway for anxiety and depression in cancer care, and mid-implementation adaptations.. <i>BMC Health Services Research</i> , 2022 , 22, 192	2.9	
115	Acceptability and appropriateness of a clinical pathway for managing anxiety and depression in cancer patients: a mixed methods study of staff perspectives. <i>BMC Health Services Research</i> , 2021 , 21, 1243	2.9	2
114	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021 , 32, e95	4	0
113	Computer-Based Decision Tools for Shared Therapeutic Decision-making in Oncology: Systematic Review. <i>JMIR Cancer</i> , 2021 , 7, e31616	3.2	3
112	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian	3.5	2
111	Best Evidence to Best Practice: Implementing an Innovative Model of Nutrition Care for Patients with Head and Neck Cancer Improves Outcomes. <i>Nutrients</i> , 2020 , 12,	6.7	12
110	Crystal Structure, Antitumour and Antibacterial Activity of Imidazo[1, 2- <i>b</i>]pyridine Ligand Containing Palladium Complexes. <i>ChemistrySelect</i> , 2020 , 5, 668-673	1.8	1
109	Dose and Sequence Dependent Synergism from the Combination of Oxaliplatin with Emetine and Patulin Against Colorectal Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020 , 20, 264-273	2.2	6
108	Utilisation of Adjuvant Chemotherapy and 5-Year Survival Analysis of Prospectively Recorded Cohort Data for Older Adults Versus Younger Adults with Resected Primary Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 988-997	1.6	
107	Cisplatin in combination with emetine and patulin showed dose and sequence dependent synergism against ovarian cancer. <i>Synergy</i> , 2020 , 10, 100060	0.9	2
106	Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
105	The value of real-world testing: a qualitative feasibility study to explore staff and organisational barriers and strategies to support implementation of a clinical pathway for the management of anxiety and depression in adult cancer patients. <i>Pilot and Feasibility Studies</i> , 2020 , 6, 109	1.9	1
104	Estimating survival time in older adults receiving chemotherapy for advanced cancer. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 617-625	3.6	3
103	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 699-709	21.7	62
102	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019 , 154, 531-538	4.9	23
101	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019 , 154, 29-37	4.9	18
100	The Elusive Search for Success: Defining and Measuring Implementation Outcomes in a Real-World Hospital Trial. <i>Frontiers in Public Health</i> , 2019 , 7, 293	6	6

99	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e86	4	10
98	Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 553-560	3.2	2
97	Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 202-209	3.6	21
96	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 97-105	3.5	3
95	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 53-60	4.9	26
94	Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 210-215	3.6	3
93	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. <i>Scientific Reports</i> , 2018 , 8, 1508	4.9	3
92	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 569-580	12.9	46
91	Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 74-83	1.9	34
90	nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, e325-e331	1.9	4
89	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 127-138	21.7	62
88	IMMU-50. THE IMMUNE LANDSCAPE OF BLOOD DENDRITIC CELLS IN GLIOBLASTOMA MULTIFORME: IMPLICATIONS FOR DC VACCINATION COMBINED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2018 , 20, vi132-vi132	1	78
87	Comparison of implementation strategies to influence adherence to the clinical pathway for screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP): study protocol of a cluster randomised controlled trial. <i>BMC Cancer</i> , 2018 , 18, 1077	4.8	20
86	Patterns of platinum drug use in an acute care setting: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1561-1568	4.9	6
85	Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 900-906	3.5	12
84	Implementation of a lung cancer multidisciplinary team standardised template for reporting to general practitioners: a mixed-method study. <i>BMJ Open</i> , 2017 , 7, e018629	3	8
83	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. <i>Disease Markers</i> , 2017 , 2017, 3098542	3.2	33
82	Changes in the in vitro activity of platinum drugs when administered in two aliquots. <i>BMC Cancer</i> , 2016 , 16, 688	4.8	5

81	Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines. <i>Anticancer Research</i> , 2016 , 36, 2809-18	2.3	11
80	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 928-36	21.7	475
79	Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4085-92	2.2	122
78	The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. <i>Supportive Care in Cancer</i> , 2015 , 23, 385-91	3.9	60
77	Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models. <i>Anticancer Research</i> , 2015 , 35, 2783-94	2.3	7
76	Combination of Genistein and Cisplatin with Two Designed Monofunctional Platinum Agents in Human Ovarian Tumour Models. <i>Anticancer Research</i> , 2015 , 35, 6027-39	2.3	7
75	Synthesis and activity of three new trinuclear platinum complexes with cis-geometry for terminal metal centres. <i>Journal of Biomedical Science</i> , 2014 , 21, 41	13.3	3
74	Single-dose methotrexate treatment for ectopic pregnancy and pregnancy of unknown location and progesterone as a predictor of success. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2014 , 54, 469-74	1.7	10
73	Gynecologic Cancer InterGroup (GCIg) consensus review for uterine and ovarian carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S55-60	3.5	78
72	Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models. <i>Anticancer Research</i> , 2014 , 34, 7077-90	2.3	4
71	Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. <i>SpringerPlus</i> , 2013 , 2, 126		13
70	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. <i>Lancet Oncology</i> , 2013 , 14, 236-43	21.7	105
69	Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. <i>Journal of Ovarian Research</i> , 2013 , 6, 78	5.5	15
68	The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3565-71	2.2	35
67	Takotsubo cardiomyopathy and 5-Fluorouracil: getting to the heart of the matter. <i>Case Reports in Oncological Medicine</i> , 2013 , 2013, 206765	0.9	15
66	Synthesis of trans-(4-hydroxypyridine)(ammine)dichloroplatinum(II) and its activity in the human ovarian tumour models. <i>Medicinal Chemistry</i> , 2013 , 9, 539-44	1.8	
65	Use of adjuvant chemotherapy in stage C (III) rectal cancer: comparison of data from matched patients in a teaching hospital's clinico-pathological database. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012 , 8, 346-55	1.9	1
64	Implementing patient question-prompt lists into routine cancer care. <i>Patient Education and Counseling</i> , 2012 , 86, 252-8	3.1	55

63	Synthesis and cytotoxicity of three trans-palladium complexes containing planaramine ligands in human ovarian tumor models. <i>ChemMedChem</i> , 2012 , 7, 1840-6	3.7	14
62	Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2012 , 20, 1235-42	3.9	152
61	Synthesis and activity of $[[\text{Cis-PtCl}(\text{NH}_3)_2]_2][\text{trans-Pt}(3\text{-Hydroxypyridine})_2(\text{H}_2\text{N}(\text{CH}_2)_6\text{NH}_2)_2]\text{Cl}_4$ in the human ovarian tumour models. <i>Medicinal Chemistry</i> , 2012 , 8, 384-91	1.8	2
60	Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. <i>Anticancer Research</i> , 2012 , 32, 53-9	2.3	40
59	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 2484-96	59.2	1454
58	Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound $[[\text{trans-PtCl}(\text{NH}_3)_2]_2[\text{trans-Pt}(\text{thiazole})_2](\text{H}_2\text{N}(\text{CH}_2)_6\text{NH}_2)_2]\text{Cl}_3(\text{NO}_3)$. <i>Medicinal Chemistry</i> , 2011 , 7, 1-8	1.8	2
57	Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2077-84	2.2	81
56	Clinical trials in recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 771-5	3.5	147
55	"The booklet helped me not to panic": a pilot of a decision aid for asymptomatic women with ovarian cancer and with rising CA-125 levels. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 737-43	3.5	10
54	Synergism from combination of cisplatin and multicentred platinum compounds coded as DH6Cl and TH1 in the human ovarian tumour models. <i>Medicinal Chemistry</i> , 2011 , 7, 593-8	1.8	
53	Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. <i>Anticancer Research</i> , 2011 , 31, 1131-40	2.3	48
52	Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration. <i>Anticancer Research</i> , 2011 , 31, 2757-62	2.3	5
51	Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. <i>Anticancer Research</i> , 2011 , 31, 3789-97	2.3	50
50	The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 342-9	1.9	58
49	Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?. <i>European Journal of Cancer</i> , 2010 , 46, 1800-7	7.5	33
48	Studies on two new mixed ligand platinum compounds with a trans-geometry. <i>Medicinal Chemistry</i> , 2010 , 6, 321-8	1.8	6
47	Identification of distinctive protein expression patterns in colorectal adenoma. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 60-70	3.1	32
46	Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: a clinical dilemma, but what would women do?. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1037-46	3.5	3

45	Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. <i>BMC Cancer</i> , 2009 , 9, 130	4.8	32
44	Studies on the synthesis and activity of three tripalladium complexes containing planaramine ligands. <i>ChemMedChem</i> , 2009 , 4, 1841-9	3.7	7
43	Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl ₂ (R-dimepyrr)] (R-dimepyrr=N-dimethyl-2(R)-aminomethylpyrrolidine). <i>European Journal of Medicinal Chemistry</i> , 2009 , 44, 2807-14	6.8	13
42	Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. <i>ANZ Journal of Surgery</i> , 2009 , 79, 685-92	1	4
41	Pleural well-differentiated papillary mesothelioma: a case report. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 920-2	8.9	7
40	Synthesis, activity and binding with DNA of [(trans-PtCl(NH ₃)) ₂](2)micro-{trans-Pd(4-hydroxypyridine) (2) (H ₂ N(CH ₂)) ₆ NH ₂)} ₂]Cl ₄ (TH8). <i>Medicinal Chemistry</i> , 2009 , 5, 372-81	1.8	8
39	Studies on New Platinum Compounds 2009 , 11-17		5
38	Synthesis and activity of a trinuclear platinum complex: [(trans-PtCl(NH ₃)) ₂] ₂ μ-[trans-Pt(3-hydroxypyridine) ₂ (H ₂ N(CH ₂)) ₆ NH ₂)]Cl ₄ in ovarian cancer cell lines. <i>ChemMedChem</i> , 2008 , 3, 145-51	3.7	24
37	Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 132-136	1.9	2
36	Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 578-82	3.8	2
35	Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. <i>Supportive Care in Cancer</i> , 2007 , 15, 301-7	3.9	96
34	Studies on the activity of three palladium(II) compounds of the form: trans-PdL ₂ Cl ₂ where L=2-hydroxypyridine, 3-hydroxypyridine, and 4-hydroxypyridine. <i>Journal of Inorganic Biochemistry</i> , 2007 , 101, 30-5	4.2	48
33	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. <i>Lancet Oncology</i> , 2007 , 8, 603-12	21.7	111
32	A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 309-16	3.5	32
31	Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. <i>Nutrition and Cancer</i> , 2006 , 55, 78-85	2.8	112
30	Predicting the toxicity of weekly docetaxel in advanced cancer. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 611-22		27
29	Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 146-51	3.8	30
28	The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours. <i>Journal of Structural Biology</i> , 2006 , 155, 38-44	3.4	88

27	Studies on the synthesis, characterization, binding with DNA and activities of two cis-planar platinum(II) complexes of the form: cis-PtL(NH ₃)Cl ₂ where L = 3-hydroxypyridine and 2,3-diaminopyridine. <i>BMC Chemical Biology</i> , 2006 , 6, 3		23
26	Not all ovarian cysts in young woman are benign: a case series and review of the management of complex adnexal masses in young women. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 350-5	1.7	2
25	An evaluation of the prevalence of malnutrition in cancer patients attending the outpatient oncology clinic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006 , 2, 80-86	1.9	22
24	XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2006 , 100, 963-71	4.2	46
23	Antitumour Activity of cis-bis(imidazo(1,2- α)-pyridine)platinum (II). <i>International Journal of Cancer Research</i> , 2006 , 2, 367-375	0.2	3
22	Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). <i>Nutrition and Cancer</i> , 2005 , 53, 51-6	2.8	90
21	Synthesis, characterization, activities, cell uptake and DNA binding of trinuclear complex: [[trans-PtCl(NH ₃)] ₂ μ-{trans-Pt(NH ₃)(2-hydroxypyridine)-(H ₂ N(CH ₂)(6)NH ₂)(2)}]Cl ₄ . <i>European Journal of Medicinal Chemistry</i> , 2005 , 40, 772-81	6.8	54
20	Synthesis, characterization and binding with DNA of four planar platinum(II) complexes of the forms: trans-PtL ₂ Cl ₂ and [PtL ₃ Cl]Cl, where L = 3-hydroxypyridine, 4-hydroxypyridine and imidazo(1,2- α)pyridine. <i>Journal of Inorganic Biochemistry</i> , 2005 , 99, 1098-112	4.2	33
19	Studies on activities, cell uptake and DNA binding of four trans-planar platinum(II) complexes of the form: trans-PtL(NH ₃)Cl ₂ , where L=2-hydroxypyridine, imidazole, 3-hydroxypyridine and imidazo(1,2- α)pyridine. <i>Journal of Inorganic Biochemistry</i> , 2004 , 98, 1261-70	4.2	35
18	The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. <i>Journal of Inorganic Biochemistry</i> , 2004 , 98, 1614-24	4.2	108
17	Studies on activities, cell up take and DNA binding of four multinuclear complexes of the form: [[trans-PtCl(NH ₃)] ₂] ₂ μ-[trans-Pd(NH ₃)(2)-(H ₂ N(CH ₂)(n)NH ₂)(2)]Cl ₄ where n=4-7. <i>Journal of Inorganic Biochemistry</i> , 2004 , 98, 1722-33	4.2	26
16	Studies on the synthesis and characterization of four trans-planar platinum(II) complexes of the form trans-PtL(NH ₃)Cl ₂ where L = 2-hydroxypyridine, 3-hydroxypyridine, imidazole, and imidazo(1,2- α)pyridine. <i>European Journal of Medicinal Chemistry</i> , 2004 , 39, 691-7	6.8	43
15	Synthesis, characterisation, activities, cell uptake and DNA binding of [[trans-PtCl(NH ₃) ₂][μ-(H ₂ N(CH ₂) ₆ NH ₂)] [trans-PdCl(NH ₃) ₂](NO ₃)Cl. <i>European Journal of Medicinal Chemistry</i> , 2004 , 39, 947-58	6.8	22
14	A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 51, 58-66	3.5	1
13	The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. <i>Journal of Biological Inorganic Chemistry</i> , 2003 , 8, 726-32	3.7	128
12	Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2003 , 43, 61-4	1.7	28
11	XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents. <i>Journal of the American Chemical Society</i> , 2003 , 125, 7524-5	16.4	121
10	Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxical effects on chemosensitivity in vitro versus in vivo. <i>International Journal of Cancer</i> , 2002 , 97, 858-63	7.5	17

9	Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2001 , 32, 173-8	5.9	7
8	Early results of chemo-radiotherapy for the definitive treatment of cervix cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2000 , 40, 341-2	1.7	
7	Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3535-44	2.2	49
6	Clinical and preclinical pharmacokinetics of raltitrexed. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 429-43	6.2	19
5	Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. <i>Journal of Inorganic Biochemistry</i> , 1999 , 77, 111-115	4.2	179
4	A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of ¹⁴ C-labelled drug. <i>Investigational New Drugs</i> , 1999 , 17, 49-56	4.3	87
3	Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 389-94	3.5	29
2	Section Review: Oncologic, Endocrine & Metabolic: Platinum agents in the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 1996 , 5, 681-693	5.9	4
1	Protein Expression Patterns in ovarian cancer cells Associated with Monofunctional Platinums Treatment		1